Free Access
| Issue |
Med Sci (Paris)
Volume 35, Number 11, Novembre 2019
Nos jeunes pousses ont du talent !
|
|
|---|---|---|
| Page(s) | 897 - 900 | |
| Section | Partenariat médecine/sciences - Écoles doctorales - Masters | |
| DOI | https://doi.org/10.1051/medsci/2019174 | |
| Published online | 17 December 2019 | |
- Walsh DM, Klyubin I, Fadeeva JV, et al. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002 ; 30 : 552–7. [PubMed] [Google Scholar]
- Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid-β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002 ; 416 : 535–9. [Google Scholar]
- Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012 ; 15 : 1227–35. [CrossRef] [PubMed] [Google Scholar]
- Um J, Kaufman A, Kostylev M, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron 2013 ; 79 : 887–902. [CrossRef] [PubMed] [Google Scholar]
- Larson M, Sherman MA, Amar F, et al. The complex PrPc -Fyn couples human oligomeric Aβ with pathological Tau changes in Alzheimer’s disease. J Neurosci 2012 ; 32 : 16857–71. [CrossRef] [PubMed] [Google Scholar]
- Brener O, Dunkelmann T, Gremer L, et al. QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers. Sci Rep 2015 ; 5 : 13222. [CrossRef] [PubMed] [Google Scholar]
- Van Groen T, Wiesehan K, Funke SA. Reduction of Alzheimer’s disease amyloid plaque load in transgenic mice by D3, a Denantiomeric peptide identified by mirror image phage display. ChemMedChem 2008 ; 3 : 1848–52. [CrossRef] [PubMed] [Google Scholar]
- Wiesehan K, Buder K, Linke RP, et al. Selection of D-amino-acid peptides that bind to Alzheimer’s disease amyloid peptide Aβ1-42 by mirror image phage display. ChemMedChem 2003 ; 4 : 748–53. [Google Scholar]
- Funke SA, Van Groen T, Kadish I, et al. Oral treatment with the D-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer’s disease transgenic mice. ACS Chem Neurosci 2010 ; 1 : 639–48. [PubMed] [Google Scholar]
- Leithold LHE, Jiang N, Post J, et al. Pharmacokinetic properties of a novel D-peptide developed to be therapeutically active against toxic β-amyloid oligomers. Pharm Res 2016 ; 33 : 328–36. [CrossRef] [PubMed] [Google Scholar]
- Kutzsche J, Schemmert S, Tusche M, et al. Large-scale oral treatment study with the four most promising D3-derivatives for the treatment of Alzheimer’s disease. Molecules 2017 ; 22 : 1693. [Google Scholar]
- Rösener NS, Gremer L, Reinartz E, et al. A D-enantiomeric peptide interferes with hetero-association of amyloid-β oligomers and prion protein. J Biol Chem 2018 ; 293 : 15748–764. [CrossRef] [PubMed] [Google Scholar]
- Cavini IA, Munte CE, Erlach MB, et al. Inhibition of amyloid Abeta aggregation by high pressures or specific d-enantiomeric peptides. Chem Commun 2018 ; 54 : 3294–7. [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.